Current evidence does not show that Ozempic causes cancer in humans. The drug carries an FDA boxed warning about thyroid tumors found in rodent studies, which understandably alarms people reading the label. But a systematic review covering 37 clinical trials and 19 real-world studies found that semaglutide use “was not associated with an increased risk of any types of cancer,” a conclusion the authors described as supported by a high grade of evidence. The picture is reassuring overall, though a few nuances are worth understanding.
Why the FDA Warning Exists
Ozempic’s label includes the most serious type of FDA warning, a boxed warning, about thyroid C-cell tumors. In rodent studies, long-term exposure to semaglutide and related drugs caused C-cell hyperplasia (abnormal cell growth) and tumors in the thyroid. That finding triggered the warning as a precaution, even though the same effect has never been observed in primates or humans.
The FDA label states it plainly: “It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.” In other words, the warning reflects uncertainty, not a confirmed human risk.
Why Rodent Results Don’t Translate Directly
The biological reason for the rodent tumors involves a receptor on thyroid C-cells that responds to semaglutide. In rats and mice, these C-cells are far more abundant in the thyroid and play a bigger role in calcium regulation. When semaglutide activates those receptors, it triggers cell growth and, over time, tumors.
Human thyroids are built differently. C-cells are sparse, scattered through the middle and upper portions of the thyroid lobes, and often hard to identify even under a microscope. Research published in The Journal of Clinical Endocrinology and Metabolism found that in one study, human C-cells tested completely negative for the receptor that semaglutide acts on. A separate analysis found the receptor present in only about 35% of human C-cells examined, and only in five of 15 thyroid lobes. This low expression helps explain why the dramatic tumor response seen in rodents hasn’t appeared in human data.
What Human Studies Actually Show
Across large clinical trials, thyroid cancer cases in semaglutide users have been rare and statistically no different from placebo groups. A systematic review in the International Journal of Molecular Sciences examined 10 studies and found thyroid cancer incidence was “notably low,” with isolated cases of papillary and medullary thyroid cancer each making up less than 1% of study participants. The large sample sizes showed no significant increase in risk.
A broader meta-analysis pooling data from trials and real-world use found the odds of thyroid cancer in semaglutide users compared to placebo were not statistically significant. The same held true when semaglutide was compared to other active diabetes medications. Overall rates of all tumors, whether benign, malignant, or unspecified, were essentially the same in semaglutide and control groups.
Pancreatic Cancer Concerns
Because semaglutide affects the pancreas (it works by mimicking a gut hormone that stimulates insulin release), questions about pancreatic cancer have also come up. A meta-analysis of 62 randomized controlled trials covering more than 66,000 patients found no significant association between GLP-1 receptor agonist use and pancreatic cancer, with a risk ratio of 1.30 that was not statistically meaningful.
One wrinkle: when researchers separated out patients who were also taking other diabetes medications, those patients showed a slightly elevated risk. But the authors noted this difference was “likely minimal,” partly because many studies excluded from the analysis had zero cancer events in both treatment and placebo groups, skewing the subset analysis. The overall conclusion was no increased pancreatic cancer risk from the drugs themselves.
Possible Protective Effects
Some evidence points in the opposite direction. A study highlighted by the National Institutes of Health found that people taking GLP-1 receptor agonists like semaglutide had a 44% lower risk of developing colorectal cancer compared to those taking insulin, and a 25% lower risk compared to those on metformin. Among people with excess weight, the protective effect was even stronger: a 50% lower risk versus insulin users and 42% lower risk versus metformin users.
Preliminary data on breast cancer recurrence has also been explored. A study presented at the American Society of Clinical Oncology compared women with stage I-III breast cancer who took semaglutide or tirzepatide to untreated patients. Recurrence rates were numerically lower in the treated group, though the differences were not statistically significant. The data was too small to draw firm conclusions, but it showed no signal of harm.
Who Should Not Take Ozempic
Despite the overall reassuring data, Ozempic is specifically contraindicated for certain people with elevated thyroid cancer risk. You should not use the drug if you or any family member has a history of medullary thyroid carcinoma, a rare type of thyroid cancer that originates in C-cells. It is also contraindicated if you have Multiple Endocrine Neoplasia syndrome type 2, a genetic condition that dramatically increases the likelihood of medullary thyroid carcinoma.
These restrictions exist because even a theoretical risk of stimulating C-cell growth is unacceptable in people already predisposed to C-cell tumors. For everyone else, the current weight of evidence shows no meaningful cancer signal from semaglutide use in humans. The FDA’s boxed warning reflects appropriate caution based on animal data, not a confirmed danger to people taking the medication.